Danaher Corporation (NYSE: DHR) Stock Competitors & Peer Comparison
See DHR's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DHR and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DHR | $200.14 | -0.19% | 140.7B | 25.07 | $7.98 | +0.72% |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.72% |
| TMO | $609.82 | +1.10% | 226.6B | 26.33 | $23.16 | +0.29% |
| NTRA | $328.93 | +0.86% | 47.1B | -249.19 | -$1.32 | N/A |
| IQV | $261.77 | +1.74% | 43.1B | 21.58 | $12.13 | N/A |
| A | $146.93 | +2.66% | 41.5B | 25.29 | $5.81 | +0.69% |
| IDXX | $504.70 | -0.36% | 39.8B | 35.49 | $14.22 | N/A |
| ILMN | $206.45 | +2.57% | 31.2B | 41.04 | $5.03 | N/A |
| WAT | $408.34 | +1.67% | 30.5B | 29.85 | $13.68 | N/A |
| MTD | $1,293.52 | +1.01% | 26.1B | 29.73 | $43.51 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
DHR vs DHR-PB Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, DHR's ROE is +0.08%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, DHR is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for DHR.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
DHR vs TMO Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, TMO has a market cap of 226.6B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while TMO trades at $609.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas TMO's P/E ratio is 26.33. In terms of profitability, DHR's ROE is +0.08%, compared to TMO's ROE of +0.13%. Regarding short-term risk, DHR is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for DHR.Check TMO's competition here
Natera, Inc. (NASDAQ: NTRA)
DHR vs NTRA Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, NTRA has a market cap of 47.1B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while NTRA trades at $328.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas NTRA's P/E ratio is -249.19. In terms of profitability, DHR's ROE is +0.08%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, DHR is similarly volatile compared to NTRA. This indicates similar risk in terms of short-term price fluctuations for DHR.Check NTRA's competition here
IQVIA Holdings Inc. (NYSE: IQV)
DHR vs IQV Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, IQV has a market cap of 43.1B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while IQV trades at $261.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas IQV's P/E ratio is 21.58. In terms of profitability, DHR's ROE is +0.08%, compared to IQV's ROE of +0.22%. Regarding short-term risk, DHR is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for DHR.Check IQV's competition here
Agilent Technologies, Inc. (NYSE: A)
DHR vs A Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, A has a market cap of 41.5B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while A trades at $146.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas A's P/E ratio is 25.29. In terms of profitability, DHR's ROE is +0.08%, compared to A's ROE of +0.20%. Regarding short-term risk, DHR is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for DHR.Check A's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
DHR vs IDXX Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, IDXX has a market cap of 39.8B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while IDXX trades at $504.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas IDXX's P/E ratio is 35.49. In terms of profitability, DHR's ROE is +0.08%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, DHR is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for DHR.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
DHR vs ILMN Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, ILMN has a market cap of 31.2B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while ILMN trades at $206.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas ILMN's P/E ratio is 41.04. In terms of profitability, DHR's ROE is +0.08%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, DHR is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for DHR.Check ILMN's competition here
Waters Corporation (NYSE: WAT)
DHR vs WAT Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, WAT has a market cap of 30.5B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while WAT trades at $408.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas WAT's P/E ratio is 29.85. In terms of profitability, DHR's ROE is +0.08%, compared to WAT's ROE of +0.02%. Regarding short-term risk, DHR is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for DHR.Check WAT's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
DHR vs MTD Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, MTD has a market cap of 26.1B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while MTD trades at $1,293.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas MTD's P/E ratio is 29.73. In terms of profitability, DHR's ROE is +0.08%, compared to MTD's ROE of -12.00%. Regarding short-term risk, DHR is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for DHR.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
DHR vs DGX Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, DGX has a market cap of 25.9B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while DGX trades at $235.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas DGX's P/E ratio is 23.18. In terms of profitability, DHR's ROE is +0.08%, compared to DGX's ROE of +0.14%. Regarding short-term risk, DHR is less volatile compared to DGX. This indicates lower risk in terms of short-term price fluctuations for DHR.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
DHR vs LH Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, LH has a market cap of 25.6B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while LH trades at $311.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas LH's P/E ratio is 18.49. In terms of profitability, DHR's ROE is +0.08%, compared to LH's ROE of +0.12%. Regarding short-term risk, DHR is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for DHR.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
DHR vs GH Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, GH has a market cap of 21.1B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while GH trades at $157.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas GH's P/E ratio is -45.09. In terms of profitability, DHR's ROE is +0.08%, compared to GH's ROE of +2.11%. Regarding short-term risk, DHR is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for DHR.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
DHR vs EXAS Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas EXAS's P/E ratio is -95.37. In terms of profitability, DHR's ROE is +0.08%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, DHR is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for DHR.Check EXAS's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
DHR vs ILMNV Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas ILMNV's P/E ratio is N/A. In terms of profitability, DHR's ROE is +0.08%, compared to ILMNV's ROE of N/A. Regarding short-term risk, DHR is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for DHR.Check ILMNV's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
DHR vs MEDP Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, MEDP has a market cap of 16.4B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while MEDP trades at $587.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas MEDP's P/E ratio is 34.44. In terms of profitability, DHR's ROE is +0.08%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, DHR is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for DHR.Check MEDP's competition here
PerkinElmer, Inc. (NYSE: PKI)
DHR vs PKI Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas PKI's P/E ratio is 41.45. In terms of profitability, DHR's ROE is +0.08%, compared to PKI's ROE of +0.03%. Regarding short-term risk, DHR is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for DHR.Check PKI's competition here
Revvity, Inc. (NYSE: RVTY)
DHR vs RVTY Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, RVTY has a market cap of 13.9B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while RVTY trades at $124.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas RVTY's P/E ratio is 23.25. In terms of profitability, DHR's ROE is +0.08%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, DHR is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for DHR.Check RVTY's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
DHR vs CRL Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, CRL has a market cap of 13.4B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while CRL trades at $278.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas CRL's P/E ratio is 28.11. In terms of profitability, DHR's ROE is +0.08%, compared to CRL's ROE of -0.08%. Regarding short-term risk, DHR is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for DHR.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
DHR vs ICLR Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, ICLR has a market cap of 13B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while ICLR trades at $169.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas ICLR's P/E ratio is 13.81. In terms of profitability, DHR's ROE is +0.08%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, DHR is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for DHR.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
DHR vs QGEN Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, QGEN has a market cap of 8.8B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while QGEN trades at $42.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas QGEN's P/E ratio is 17.54. In terms of profitability, DHR's ROE is +0.08%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, DHR is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for DHR.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
DHR vs RDNT Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, RDNT has a market cap of 5.9B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while RDNT trades at $75.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas RDNT's P/E ratio is 164.11. In terms of profitability, DHR's ROE is +0.08%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, DHR is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for DHR.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
DHR vs SHC Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while SHC trades at $18.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas SHC's P/E ratio is 19.14. In terms of profitability, DHR's ROE is +0.08%, compared to SHC's ROE of +0.27%. Regarding short-term risk, DHR is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for DHR.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
DHR vs BLLN Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, BLLN has a market cap of 4.5B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while BLLN trades at $98.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas BLLN's P/E ratio is 141.10. In terms of profitability, DHR's ROE is +0.08%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, DHR is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for DHR.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
DHR vs SYNH Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas SYNH's P/E ratio is 61.40. In terms of profitability, DHR's ROE is +0.08%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, DHR is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for DHR.Check SYNH's competition here
GRAIL Inc. (NASDAQ: GRAL)
DHR vs GRAL Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, GRAL has a market cap of 3.3B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while GRAL trades at $76.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas GRAL's P/E ratio is -7.82. In terms of profitability, DHR's ROE is +0.08%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, DHR is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for DHR.Check GRAL's competition here
Veracyte, Inc. (NASDAQ: VCYT)
DHR vs VCYT Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, VCYT has a market cap of 3.3B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while VCYT trades at $40.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas VCYT's P/E ratio is 20.43. In terms of profitability, DHR's ROE is +0.08%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, DHR is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for DHR.Check VCYT's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
DHR vs OLK Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas OLK's P/E ratio is -96.59. In terms of profitability, DHR's ROE is +0.08%, compared to OLK's ROE of -0.07%. Regarding short-term risk, DHR is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for DHR.Check OLK's competition here
CareDx, Inc (NASDAQ: CDNA)
DHR vs CDNA Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, CDNA has a market cap of 2.6B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while CDNA trades at $50.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas CDNA's P/E ratio is 59.83. In terms of profitability, DHR's ROE is +0.08%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, DHR is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for DHR.Check CDNA's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
DHR vs WGS Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, WGS has a market cap of 2.5B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while WGS trades at $85.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas WGS's P/E ratio is 236.85. In terms of profitability, DHR's ROE is +0.08%, compared to WGS's ROE of -0.39%. Regarding short-term risk, DHR is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for DHR.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
DHR vs PSNL Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while PSNL trades at $16.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas PSNL's P/E ratio is -14.88. In terms of profitability, DHR's ROE is +0.08%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, DHR is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for DHR.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
DHR vs OPK Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while OPK trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas OPK's P/E ratio is -5.81. In terms of profitability, DHR's ROE is +0.08%, compared to OPK's ROE of -0.06%. Regarding short-term risk, DHR is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for DHR.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
DHR vs CSTL Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, CSTL has a market cap of 987.7M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while CSTL trades at $32.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas CSTL's P/E ratio is -48.98. In terms of profitability, DHR's ROE is +0.08%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, DHR is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for DHR.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
DHR vs FLGT Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, FLGT has a market cap of 580.8M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while FLGT trades at $20.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas FLGT's P/E ratio is 2045.00. In terms of profitability, DHR's ROE is +0.08%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, DHR is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for DHR.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
DHR vs GRALV Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas GRALV's P/E ratio is N/A. In terms of profitability, DHR's ROE is +0.08%, compared to GRALV's ROE of N/A. Regarding short-term risk, DHR is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for DHR.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
DHR vs NEO Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, NEO has a market cap of 445M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while NEO trades at $17.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas NEO's P/E ratio is 133.23. In terms of profitability, DHR's ROE is +0.08%, compared to NEO's ROE of -0.06%. Regarding short-term risk, DHR is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for DHR.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
DHR vs CO Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas CO's P/E ratio is 5.06. In terms of profitability, DHR's ROE is +0.08%, compared to CO's ROE of +0.11%. Regarding short-term risk, DHR is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for DHR.Check CO's competition here
Prenetics Global Limited (NASDAQ: PRENW)
DHR vs PRENW Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, PRENW has a market cap of 325.8M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas PRENW's P/E ratio is N/A. In terms of profitability, DHR's ROE is +0.08%, compared to PRENW's ROE of -0.49%. Regarding short-term risk, DHR is less volatile compared to PRENW. This indicates lower risk in terms of short-term price fluctuations for DHR.Check PRENW's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
DHR vs MYGN Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, MYGN has a market cap of 323M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while MYGN trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas MYGN's P/E ratio is -26.31. In terms of profitability, DHR's ROE is +0.08%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, DHR is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for DHR.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
DHR vs FLDM Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas FLDM's P/E ratio is -4.74. In terms of profitability, DHR's ROE is +0.08%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, DHR is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for DHR.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
DHR vs BDSX Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, BDSX has a market cap of 219.5M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while BDSX trades at $26.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas BDSX's P/E ratio is -8.51. In terms of profitability, DHR's ROE is +0.08%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, DHR is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for DHR.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
DHR vs XGN Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, XGN has a market cap of 169.8M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while XGN trades at $7.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas XGN's P/E ratio is -8.68. In terms of profitability, DHR's ROE is +0.08%, compared to XGN's ROE of -1.22%. Regarding short-term risk, DHR is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for DHR.Check XGN's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
DHR vs IMDX Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, IMDX has a market cap of 135.6M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while IMDX trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas IMDX's P/E ratio is -2.82. In terms of profitability, DHR's ROE is +0.08%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, DHR is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for DHR.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
DHR vs GTH Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas GTH's P/E ratio is -1.11. In terms of profitability, DHR's ROE is +0.08%, compared to GTH's ROE of -1.01%. Regarding short-term risk, DHR is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for DHR.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
DHR vs GENE Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas GENE's P/E ratio is -38.25. In terms of profitability, DHR's ROE is +0.08%, compared to GENE's ROE of -1.85%. Regarding short-term risk, DHR is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for DHR.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
DHR vs SERA Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, SERA has a market cap of 76.4M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while SERA trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas SERA's P/E ratio is -3.08. In terms of profitability, DHR's ROE is +0.08%, compared to SERA's ROE of -0.47%. Regarding short-term risk, DHR is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for DHR.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
DHR vs PRPO Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, PRPO has a market cap of 48.7M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while PRPO trades at $27.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas PRPO's P/E ratio is -105.08. In terms of profitability, DHR's ROE is +0.08%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, DHR is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for DHR.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
DHR vs MDXH Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, MDXH has a market cap of 36.2M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while MDXH trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas MDXH's P/E ratio is -1.85. In terms of profitability, DHR's ROE is +0.08%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, DHR is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for DHR.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
DHR vs QUCY Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, QUCY has a market cap of 30.7M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while QUCY trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas QUCY's P/E ratio is -0.06. In terms of profitability, DHR's ROE is +0.08%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, DHR is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for DHR.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
DHR vs AKU Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas AKU's P/E ratio is -0.13. In terms of profitability, DHR's ROE is +0.08%, compared to AKU's ROE of -5.32%. Regarding short-term risk, DHR is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for DHR.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
DHR vs CEMI Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas CEMI's P/E ratio is -0.63. In terms of profitability, DHR's ROE is +0.08%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, DHR is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for DHR.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
DHR vs ENZ Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas ENZ's P/E ratio is -2.24. In terms of profitability, DHR's ROE is +0.08%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, DHR is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for DHR.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
DHR vs PMD Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas PMD's P/E ratio is -5.24. In terms of profitability, DHR's ROE is +0.08%, compared to PMD's ROE of -0.32%. Regarding short-term risk, DHR is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for DHR.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
DHR vs ME Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas ME's P/E ratio is -0.03. In terms of profitability, DHR's ROE is +0.08%, compared to ME's ROE of -42.03%. Regarding short-term risk, DHR is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for DHR.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
DHR vs MYNZ Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, DHR's ROE is +0.08%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, DHR is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for DHR.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
DHR vs BNR Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, BNR has a market cap of 12.8M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while BNR trades at $12.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas BNR's P/E ratio is -13.89. In terms of profitability, DHR's ROE is +0.08%, compared to BNR's ROE of -0.11%. Regarding short-term risk, DHR is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for DHR.Check BNR's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
DHR vs ADVB Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, ADVB has a market cap of 11.3M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while ADVB trades at $8.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas ADVB's P/E ratio is -74.45. In terms of profitability, DHR's ROE is +0.08%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, DHR is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for DHR.Check ADVB's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
DHR vs CHEK Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas CHEK's P/E ratio is -0.43. In terms of profitability, DHR's ROE is +0.08%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, DHR is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for DHR.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
DHR vs CNTG Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas CNTG's P/E ratio is -0.23. In terms of profitability, DHR's ROE is +0.08%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, DHR is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for DHR.Check CNTG's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
DHR vs BIAFW Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, BIAFW has a market cap of 8.5M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while BIAFW trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas BIAFW's P/E ratio is 0.90. In terms of profitability, DHR's ROE is +0.08%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, DHR is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for DHR.Check BIAFW's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
DHR vs APDN Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas APDN's P/E ratio is -0.10. In terms of profitability, DHR's ROE is +0.08%, compared to APDN's ROE of -7.23%. Regarding short-term risk, DHR is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for DHR.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
DHR vs NDRA Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, NDRA has a market cap of 7.2M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while NDRA trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas NDRA's P/E ratio is -0.73. In terms of profitability, DHR's ROE is +0.08%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, DHR is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for DHR.Check NDRA's competition here
Invitae Corporation (NYSE: NVTA)
DHR vs NVTA Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas NVTA's P/E ratio is -0.00. In terms of profitability, DHR's ROE is +0.08%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, DHR is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for DHR.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
DHR vs LMDXW Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, DHR's ROE is +0.08%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, DHR is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for DHR.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
DHR vs LMDX Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas LMDX's P/E ratio is -0.01. In terms of profitability, DHR's ROE is +0.08%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, DHR is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for DHR.Check LMDX's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
DHR vs BIAF Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, BIAF has a market cap of 3.3M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while BIAF trades at $7.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas BIAF's P/E ratio is -0.93. In terms of profitability, DHR's ROE is +0.08%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, DHR is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for DHR.Check BIAF's competition here
DermTech, Inc. (NASDAQ: DMTK)
DHR vs DMTK Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas DMTK's P/E ratio is -0.04. In terms of profitability, DHR's ROE is +0.08%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, DHR is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for DHR.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
DHR vs NOTV Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas NOTV's P/E ratio is -0.03. In terms of profitability, DHR's ROE is +0.08%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, DHR is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for DHR.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
DHR vs SQL Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas SQL's P/E ratio is -0.40. In terms of profitability, DHR's ROE is +0.08%, compared to SQL's ROE of -30.46%. Regarding short-term risk, DHR is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for DHR.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
DHR vs AWH Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas AWH's P/E ratio is -0.09. In terms of profitability, DHR's ROE is +0.08%, compared to AWH's ROE of +1.62%. Regarding short-term risk, DHR is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for DHR.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
DHR vs HTGM Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas HTGM's P/E ratio is -0.03. In terms of profitability, DHR's ROE is +0.08%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, DHR is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for DHR.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
DHR vs BIOC Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas BIOC's P/E ratio is -0.01. In terms of profitability, DHR's ROE is +0.08%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, DHR is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for DHR.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
DHR vs ISPC Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, ISPC has a market cap of 204.1K. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while ISPC trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas ISPC's P/E ratio is -0.05. In terms of profitability, DHR's ROE is +0.08%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, DHR is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for DHR.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
DHR vs SQLLW Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, DHR's ROE is +0.08%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, DHR is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for DHR.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
DHR vs WGSWW Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, DHR's ROE is +0.08%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, DHR is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for DHR.Check WGSWW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
DHR vs BNGOW Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas BNGOW's P/E ratio is N/A. In terms of profitability, DHR's ROE is +0.08%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, DHR is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for DHR.Check BNGOW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
DHR vs PRXL Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas PRXL's P/E ratio is 42.97. In terms of profitability, DHR's ROE is +0.08%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, DHR is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for DHR.Check PRXL's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
DHR vs MEUSW Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas MEUSW's P/E ratio is N/A. In terms of profitability, DHR's ROE is +0.08%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, DHR is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for DHR.Check MEUSW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
DHR vs CHEKZ Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, DHR's ROE is +0.08%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, DHR is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for DHR.Check CHEKZ's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
DHR vs OCDX Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas OCDX's P/E ratio is -42.28. In terms of profitability, DHR's ROE is +0.08%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, DHR is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for DHR.Check OCDX's competition here
Danaher Corporation (NYSE: DHR-PA)
DHR vs DHR-PA Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, DHR's ROE is +0.08%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, DHR is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for DHR.Check DHR-PA's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
DHR vs NDRAW Comparison September 2026
Danaher Corporation (NYSE: DHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR stands at 140.7B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, DHR is priced at $200.14 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR currently has a P/E ratio of 25.07, whereas NDRAW's P/E ratio is N/A. In terms of profitability, DHR's ROE is +0.08%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, DHR is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for DHR.Check NDRAW's competition here